197 results about "Pulmonary heart disease" patented technology

The invention relates to Chinese traditional medicine technology field, it is a Chinese traditional medicine compound for curing pulmonary heart diseases. It includes Chinese herbal medicines lepidium seed, chuanxiong rhizome, its character lies in: the prescription is made up of 1-3 shares of lepidium seed or its extract, 1-2 shares of chuanxiong rhizome or its extract and proper quantity of accessories. Compared with current technology, the medicine reduces the carbon dioxide branch pressure, upgrades the effect of the high oxygen branch pressure, and supplements the blank of Chinese patent medicine injection solution for curing pulmonary heart diseases. It overcomes the deficiencies that the curative effect is low, and the side effect is large and not ideal. The investment is little, and the cost is low.

The present invention is one kind of the recipe and preparation process of cardiopulmonary disease treating Chinese medicine composition. The Chinese medicine composition includes main material comprising astragalus root, pepperweed seed, Chuanxiong rhizome and trichosanthes peel, as well as supplementary material. The Chinese medicine composition as one kind of Chinese medicine injection for treating cardiopulmonary disease is superior to available medicines in that it can obviously lower CO2 partial pressure and raise oxygen partial pressure.

The invention discloses a medicine for treating cough. The medicine adopts Cortex Mori, Radix Panacis Quinquefolii, Bulbus Fritillariae Unibracteatae, Cordyceps, Radix Scutellariae, Radix Saposhnikoviae, Fructus Forsythiae, Radix Aucklandiae, Cortex Magnoliae Officinalis, Radix Platycodi, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis, Radix Astragali, Flos Lonicerae, Endothelium Corneum Gigeriae Galli, Rhizoma Atractylodis Macrocephalae, Herba Ephedrae, Poria and Roasted Radix Glycyrrhizae as the raw materials. The drugs are dried, crushed and prepared into power or capsules. The invention is used for treating chronic bronchitis, allelgic asthma, emphysema, pulmonary heart disease and high blood pressure and has the advantages of quick relieving cough, eliminating phlegm and relieving asthma, enhancing appetite, promoting digestion, the most remarkable characteristic of both temporary solution and permanent cure, good long term effect.

The invention provides a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, its preparing process and quality control method, wherein Dipyridamole and total glycosides of codonopsis pilosula are employed in combination to obtain various dose forms of injections and oral administration preparations. The composite preparation is mainly used for treating coronary disease, pulmonary heart disease, cerebral ischemia, nervous prostration, climacteric metancholia, The preparation of the invention has the advantages of high purity, ensured constituents, controllable quality, improved curative effect, wider range of safely, and less fluctuation of treatment effects.

The invention discloses a tanshinone IIA phosphoric acid derivative and synthesis and use thereof as a medicine for treatment. In particular, the present invention provides a novel derivative shown as a general formula (I) and a pharmaceutically acceptable salt thereof or a pharmaceutical composition containing the novel derivative shown as the general formula (I), and a method for preparing the novel derivative shown as the general formula (I). The invention also discloses use of the novel derivative, the pharmaceutically acceptable salt thereof or the pharmaceutical composition containing the novel derivative in preparation of medicines for treatment of coronary heart disease, angina, myocardial infarction, viral myocarditis, arrhythmia, cerebrovascular disease, hepatitis, pulmonary heart disease, bronchial asthma, cancer, kidney disease, eye disease, thromboangiitis obliterans, hypertension, fractures, burns, surgical operations or behcet ' s syndrome. On the basis of ensurance of the activity of tanshinone IIA, the novel derivative, the water solubility of the pharmaceutically acceptable salt thereof or the pharmaceutical composition containing the novel derivative can be improved. Compared with tanshinone IIA sodium sulfonate, the stability is improved, and because the acidity of the pharmaceutically acceptable salt thereof or the pharmaceutical composition containing the novel derivative is reduced obviously, injection stimulation can be avoided. All substituents of the general formula (I) are as defined in the specification.

The invention relates to an ambroxol hydrochloride solution for inhalation and a preparation method thereof. Ambroxol hydrochloride is used as an active ingredient. The ambroxol hydrochloride solution belongs to a sterile inhalation preparation capable of being used for treating diseases such as bronchial asthma, chronic bronchitis, emphysema, pulmonary heart diseases, pulmonary infection and COPD (chronic obstructive pulmonary diseases).

The invention discloses fritillaria superfine powder as well as a preparation method and application thereof. The preparation method comprises the following steps: step 1, selecting materials and cleaning; step 2, drying and sterilizing; step 3, grinding and pulping; step 4, pre-freezing slurry; step 5, freezing and drying; step 6, smashing for multiple times into the fritillaria superfine powder with a grain size of 0.5-2 [mu]m. The fritillaria superfine powder is prepared by the preparation method. The fritillaria superfine powder prepared by the preparation method is taken as an only active ingredient to be applied to the preparation of a drug for treating a pulmonary disease. The fritillaria superfine powder disclosed by the invention is used for treating pneumothorax, pulmonary bullous, emphysema, pulmonary shadow, lung cancer, pulmonary heart disease, respiratory failure, pulmonary embolism, pulmonary abscess, pneumonia, neonatal pneumonia, infantile pneumonia, trachitis, asthma, pulmonary tuberculosis, pneumoconiosis and / or interstitial lung disease and has the advantages that the treatment effect is obvious, the condition of a patient is stable, the life quality of the patient is improved, the weight of the patient is increased, the immune function of the patient is improved, and the medication is safe.

The invention discloses a lung-clearing asthma-relieving phlegm-reducing Chinese patent drug comprising the following components in parts by weight: 10-20 affine cudweed, 10-20 geranium wilfordii, 20-40 golden buckwheat rhizome, 5-15 fructus persicae immaturus, 10-20 isatis roots, 5-15 liquorice, 5-15 radix stemonae, 5-15 shizandra berries, 10-20 scrophularia ningpoensis, 20-40 concha ostreae and10-30 fructus trichosanthis. A preparation method of the lung-clearing asthma-relieving phlegm-reducing Chinese patent drug comprises the following steps of: (1) firstly coarsely crushing the components, and then uniformly mixing; (2) finely crushing to a grain diameter of less than 5 mum, and carrying out micropowder crystallization. The lung-clearing asthma-relieving phlegm-reducing Chinese patent drug can generate the pharmacological effects of clearing lung heat, resisting bacteria and inflammation, relieving coughs, eliminating phlegm, relieving asthma, nourishing yin, moistening lung, tonifying qi, and the like through the mixed and synergetic effects of the effective components of Chinese medicinal herbs and has good effects on respiratory system diseases, i.e. bronchial asthma, acute and chronic bronchitis, pneumonia, emphysema, pleural effusion, pulmonary heart diseases, chronic pharyngolaryngitis, difficult sleeping due to night cough, and the like after being taken.

The invention relates to a traditional Chinese medicine preparation for curing cough and asthma, which belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine preparation is characterized by being prepared by the following traditional Chinese medicines according to the weight percentage: 70g of sichuan fritillary bulb, 100g of liquorice, 50g of tabasheer, 5g of cinnabar, 1g of Chinese ephedra, 50g of cnidium fruit, 50g of coltsfoot flower and 100g of pinellia tuber; and the medicines are accurately weighed according to a medical prescription, cleanly selected, respectively ground into fine powder, extremely ground into delicate powder, sieved with 120 meshes and then put up in capsules after sterilization. The traditional Chinese medicine preparation for curing cough and asthma can be used for various coughs and asthmas, has the effects of reducing sputum, relieving cough and relieving asthma, has special effects for curing acute and chronic trachitis, bronchitls, emphysema, pulmonary heart disease and cough and asthma and has the characteristics of short treatment course, fast effect and high curative ratio. After the statistics on clinical therapeutic effects to 500 patients, the total effective rate can reach 98 percent and the curative ratio is up to over 80 percent.